Manual for Submission of Changes, Amendments, Suspensions, and Cancellations v.1
|
|
- Jemimah Hamilton
- 8 years ago
- Views:
Transcription
1 [Brazilian Health Surveillance Agency] Manual for Submission of Changes, Amendments, Suspensions, and Cancellations v.1 Brasília, 2015
2 Copyright 2015: Brazilian Health Surveillance Agency. The partial or total reproduction of this manual is allowed only when its source is referred. Legal Deposit at National Library, as Decree # 1,825 of December 20, Director-President Jaime César de Moura Oliveira Associate Director-President Diogo Penha Soares Directors José Carlos Magalhães da Silva Moutinho Renato Alencar Porto Ivo Bucaresky Head of Office Luciana Shimizu Takara Superintendent of Drugs and Biological Products Meiruze Sousa Freitas Clinical Research Coordination on Drugs and Biological Products Patrícia Ferrari Andreotti Direct Participation: André Luis Carvalho Santos Souza Bruno Zago França Diniz Candida Luci Pessoa e Silva Sônia Costa e Silva Cooperation: Adriane Alves de Oliveira Bruno de Paula Coutinho Carla Abrahao Brichesi Carlos Augusto Martins Netto Claudio Nishizawa Fanny Nascimento Moura Fernando Casseb Flosi Flávia Regina Souza Sobral Janaina Lopes Domingos Kellen do Rocio Malaman Miriam Motizuki Onishi Patrícia Ferrari Andreotti Ricardo Eccard da Silva
3 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 1 Table of Contents 1. Introduction Changes to DDCM Amendments to the Protocol Suspensions and Cancellations References Annexes... 14
4 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 2 1. Introduction Without prejudice to the existing regulations in legal provisions, this manual aims to guide the submissions of modifications to the Drugs Clinical Development Dossier (DDCM), amendments to the clinical protocols, suspensions, and cancellations according to chapters IV, V, and VI of the Collegial Board of Governor s Resolution (RDC 09/2015). The document breaks down into specific sections for each type of change. The changes are described in details, with examples and their specific petition application issues. This manual is non-binding regulatory provision adopted as a complement to the health legislation with the educational purpose to guide on routines and procedures for compliance with the legislation and is not intended to expand or restrict technical or administrative requirements. The guidelines contained in this manual are subject to the receipt of society suggestions in the manner and for a period to be established by ANVISA. Thus, this manual is open to contributions to recurrent review process. The suggestions received will be evaluated to support the manual revision and consequent new version of publication, at every update. We emphasize that the situations and examples mentioned in this manual are illustrative, but by no means, exhaustive or restrictive. Each situation must be assessed on a case-by-case basis, and contexts lying outside the ones herein described shall be always followed by rationales.
5 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 3 2. Changes to DDCM Changes to DDCM, in the context of RDC 09/2015, are defined as any changes made to the overall context of DDCM - specifically those related to the quality of the investigational product - or administrative changes, such as form updates. All changes must be submitted to ANVISA: substantial changes shall be filed, when their performing and implementation must await manifestation, while the nonsubstantial changes shall be submitted as part of the safety update report regarding the experimental drug development. Details on the procedures for petitioning are described below. Substantial Changes can be filed at any time after the initial submission of DDCM, even before the final manifestation by ANVISA. For the purposes of Resolution, substantial changes are: I Inclusion of clinical trial protocol(s) not foreseen or different from that (those) previously established in the initial development plan; II Exclusion of clinical trial protocol(s); III Amendments that may potentially generate impact to the quality or safety of the investigational drug, active comparator, or placebo. It is the responsibility of the sponsor to assess whether a change is considered substantial or not and its impact on the clinical development. This assessment should always be made on a case-by-case basis, based on the aforementioned criteria and on the examples below. The following are examples of substantial changes related to the quality or safety of the investigational product. We emphasize that the lists below are illustrative only, not exhausting all the possibilities:
6 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 4 1. Substantial Changes: a. Changes related to the active pharmaceutical ingredient; b. Changes related to the quality control and stability of the active pharmaceutical ingredient and investigational product; c. Changes related to the excipient quality control; d. Changes of description and composition the investigational product; e. Changes related to the manufacturing place of the investigational product; f. Changes related to the manufacturing process of the investigational product; g. Changes related to the manufacturing equipment of the investigational product; h. Changes related to the batch size of the investigational product; i. Changes related to the packaging of the investigational product; j. Inclusion of new dosage form; k. Changes related to the shelf life or the conservation care of the investigational product; l. Inclusion of new concentration; m. Inclusion of new dosage form; n. Changes related to the dosage; o. Use magnification; p. Addition of a new route of administration; q. Addition of a new therapeutic indication; 2. Non-substantial changes: a. Update of DDCM Application Form; b. Labeling change of the investigational product; c. Update of the comparator drug package insert; d. Spell check in documents; e. Minor clarifications. For changes of any information contained in the Form, the submission of new form with updated information and document describing the reasons for each change is enough. The clinical trial amendment is not a change, as explained in the next section.
7 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 5 It is recommended that substantial changes are accompanied by a comparative table, if applicable. The applicant must update the forms whenever there is a change in the data therein contained (and not just at the time of submission of annual reports, for example), because this data reflect the advertising of clinical trials at ANVISA website and will be used to guide inspections in Good Clinical Practices. The update for this form does not depend on the Agency s prior approval. Substantial changes should be secondary to the primary petition of DDCM submission for the experimental drug. The inclusion and exclusion of clinical trials have their own issues, namely: CLINICAL TRIALS Changes of DDCM Inclusion of clinical trial protocol not foreseen in the initial development plan o The inclusion of the clinical trial protocols that were already foreseen in the initial development plan should be done using specific subject as Manual for Submission of Drug Clinical Development Dossier (DDCM) and Specific Clinical Trial Dossier CLINICAL TRIALS - Changes of DDCM Exclusion of clinical trial protocol The changes that potentially generate impact on the quality or safety of the investigational drug, active comparator or placebo as examples above, should use the petitions subject CLINICAL TRIALS Changes of DDCM Changes that may potentially generate impact on the quality or safety of the investigational product. (Comparative) documentation of the initial situation and of the proposal must be submitted accompanied by technical rationale and any additional documents required to prove that the change will not impact on the clinical development of the product.
8 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 6 It is noteworthy to highlight that it is the responsibility of the sponsor to evaluate and classify the changes prior to submission to the Agency, so that a risk/benefit analysis and the need for supporting documentation is performed. As a suggestion for greater flexibility and ease of submitting the changes to the analysis, the Annex I of this manual can be, optionally, completed and submitted along with other documents. Non-substantial changes do not have a specific petition subject and should be integrated to the petition CLINICAL TRIALS Update Safety Report of the Investigational Drug Development.
9 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 7 3. Amendments to the Protocol Amendments, in the context of RDC 09/2015, are defined as any changes made to the clinical protocol, whether they are substantial or not. All amendments must be submitted to ANVISA: substantial amendments shall be filed, when their performing and implementation must await manifestation, while non-substantial changes must be submitted as part of the annual report of the clinical trial. Details on the procedures for filing will be described below. Substantial amendments may be filed at any time after the inclusion of the first clinical protocol to DDCM, even before the final manifestation by ANVISA. met: Substantial changes are those where one or more of the following criteria are Changes in the clinical trial protocol affecting the safety or physical or mental integrity of individuals; Change in the scientific value of the clinical trial protocol; Conceptually, a clinical trial has scientific value if: a) Assess a therapeutic or diagnostic intervention that can lead to improvements in health and quality of life; or b) For an etiologic, physiopathological, or preliminary epidemiological study to develop such intervention; or
10 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 8 c) Test a hypothesis that can generate important knowledge about the structure or the functioning of human biological systems, even if this knowledge has no immediate practical ramifications. Thus, scientific value change examples are switching from a placebo comparator to an active comparator, the inclusion of additional experimental arms or changes in the statistical analysis plan. It is the responsibility of the sponsor to assess whether an amendment is considered significant or not and its impact on clinical development. This assessment should always be made on a case-by-case basis, based on the aforementioned criteria. Here are some examples for each category of amendments, including examples of situations that do not constitute an amendment. Note that the list below is illustrative only, not exhausting all possibilities. 1. Substantial Amendments: a. Change of the primary objective of the clinical protocol; b. Change of the primary or secondary endpoints; c. Using new parameter to measure the primary endpoint; d. New information or interpretation of pharmacological or toxicological data, which may impact on the risk analysis; e. Change in the criteria established for protocol completion, even though it has already done; f. Addition of experimental arm or placebo arm; g. Change in the number of participants expected for the study; h. Change in the inclusion and exclusion criteria; i. Reduction in the number of scheduled visits; j. Change in medical monitoring or diagnostic procedures; k. Removing the Data Monitoring Independent Committee originally planned for the study; l. Change in the investigational product;
11 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 9 m. Change of dosage of the investigational product; n. Change in route of administration of the investigational product; o. Change in the clinical protocol design; p. Change to the original statistical analysis plan. 2. Non-substantial amendments: a. Change, addition, or removal of exploratory endpoints; b. Proposals for extending or continuing research with the same recruited participants, without change in the design, methods and objectives of the original project. In the case any of these changes takes place, another research protocol must be submitted, not an amendment; c. Change in the documentation used by the study team to capture and record the data; d. Addition of preventive security monitoring addition, not related to any issued security advisories. e. Minor clarifications to the protocol; f. Spell check; g. Update of the Clinical Trial Presentation Form. The applicant must update the Clinical Trial Presentation Form whenever there is a change in the data contained therein (and not just at the time of submission of annual reports, for example), because this data reflects the advertising of clinical trials at the website of ANVISA and will be used to guide inspections for Good Clinical Practices. The update for this form does not depend on prior approval of the Agency, except where: Change in the title or in the code of the clinical trial protocol; Inclusion or exclusion of the investigational product to be imported Change in storage and conditions and shelf life of the investigational products. For these cases, a new version of the CE will be issued. 3. Examples that do not constitute amendments to the protocol:
12 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 10 a. Investigator's Brochure update. This should be petitioned as CLINICAL TRIALS Investigator s Brochure Update, unless it also substantiates changes to the clinical protocol. In this case, the change must be evaluated by the Sponsor and rated as substantial or not, and respective procedures must be followed. b. Changes in the DDCM submission form or in accompanying documents. These should be petitioned as CLINICAL TRIALS - Change of DDCM Application Form. c. Changes in the submission form of the clinical protocol. These should be petitioned as CLINICAL TRIALS - Change of Clinical Trial Presentation Form. d. Proposal to extend the clinical protocol in which is provided for design change, methods, or objectives. For this type of change, a new clinical protocol should be added to DDCM, not fitting amendment to the protocol already submitted, as explained in the examples of non-substantial amendments. e. Exclusion, cancellation, suspension, or reactivation of clinical trial protocol. Substantial amendments should be secondary to the primary petition that entered the clinical protocol in DDCM for the investigational product. As a suggestion for greater flexibility and ease of submitting amendments to the analysis, the Annex II of this manual can be completed and submitted along with other documents, optionally. The specific subject of petition is CLINICAL TRIALS - Substantial Amendment to Clinical Protocol. Non-substantial amendments do not have a specific application subject and should be integrated into the application in CLINICAL TRIALS - Annual Clinical Trial Follow-up Protocol with the same documents required for substantial amendments.
13 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations Suspensions and Cancellations For DDCM: A DDCM may be canceled or suspended. These situations have their own petition subjects and should not constitute any of the petitions of the aforementioned changes. After suspension or cancellation decision, the sponsor must notify ANVISA within 15 calendar days. If the cancellation occurs through the request of the company, including cases of cancellation for safety reasons, the petitions subject CLINICAL TRIALS - DDCM cancellation request should be used; if cancellation happens for global transfer of responsibility, the petition subject is CLINICAL TRIALS - DDCM cancellation due to global transfer of responsibility for Responsible Sponsor. Please note that cancellations under RDC 09/2015, are definitive, with no possibility of subsequent reactivation, and that once a DDCM is cancelled, no clinical trials related thereto may be continued in the country. In the specific case of DDCM cancellation request, applications to be submitted to the following-up plan and for measures to minimize/mitigate the risk of participants in clinical trials already ongoing are detailed in the Manual for Adverse Event and Safety Clinical Trials Monitoring. It is important to remember that for a DDCM, cancellation can occur at any time, even though it has not yet been assessed. For suspensions, the subject to be used is CLINICAL TRIALS - Temporary suspension of DDCM. By definition, these have a temporary character and can be reversed with the petition subject CLINICAL TRIALS - Reactivation of suspended DDCM. Reactivation is subject to prior approval by ANVISA.
14 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 12 For a Clinical Trial: As well as the DDCM, an individual clinical trial can be canceled or suspended. These situations have their own petition subject and should not constitute any of the petitions of the aforementioned amendments. After suspension or cancellation decision, the sponsor must notify ANVISA within 15 calendar days, except in cases of temporary suspension as an immediate safety measure, when the deadline is 7 calendar days from the date of suspension. In addition, cancellations under RDC 09/2015, are definitive, with no possibility of subsequent reactivation. It is important to remember that the cancellation only applies to clinical trial protocols that have been initiated by the sponsor. If the protocol is provided in DDCM, but has not been started yet, the exclusion of the protocol should be made, as provided in the previous section. If the cancellation happens as a request of the company, including cases of cancellation for security reasons, the petition subject CLINICAL TRIALS request of Clinical Trial Protocol cancellation should be used; if cancellation happens for global transfer of responsibility, the petition subject CLINICAL TRIALS - Clinical Trial Protocol Cancellation due to global transfer of responsibility. In the specific case of the cancellation request, the requirements to be submitted to the monitoring plan and for measures to minimize/mitigate the risk of trial participants are detailed in the Manual for Adverse Event and Safety Monitoring in Clinical Trials. For suspensions, the subject to be used is CLINICAL TRIALS - Temporary suspension of Clinical Trial Protocol. By definition, these have a temporary character and can be reversed with the petition subject CLINICAL TRIALS suspended Clinical Trial Protocol Reactivation. Reactivation is subject to prior approval by ANVISA.
15 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations References BRASIL. ANVISA. Agência Nacional de Vigilância Sanitária. Resolução RDC n 09, de 20 de Fevereiro de 2015, publicada no D.O.U. de 03 de Março de Dispõe sobre o regulamento para a realização de ensaios clínicos com medicamentos no Brasil. Diário Oficial da União; Poder Executivo, de 03 de Março de EUROPEAN COMISSION. Communication from the Commission Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT-1). Available at: Access on 20 Nov FOOD AND DRUG ADMINISTRATION. IND Application Reporting: Protocol Amendments. Available at: ndapproved/approvalapplications/investigationalnewdrugindapplication/ucm htm. Access on 19 Nov HEALTH CANADA. Guidance Document For Clinical Trial Sponsors: Clinical Trial Applications. Available at: Access on 21 Nov 2014.
16 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 14 Annexes ANNEX I PETITION FORM FOR SUBSTANTIAL CHANGE OF THE DRUG CLINICAL DEVELOPMENT DOSSIER (DDCM) Brazilian Health Surveillance Agency Clinical Research Petition Form for Substantial Change of the Drug Clinical Development Dossier (DDMC) Document Identification (For use of the receiver body) 1. Process Number 2. Expedient (Day/ Month/ Year) Company Data 3. Applicant Manufacturer 5. Number of Authorization/Registration Number of Authorization/Registration DDMC Data 7. Number of the dossier process for drug clinical development (DDMC): 8 Change Type: a) Inclusion of clinical trial protocol(s) not foreseen or different from those previously established in the initial development plan? b) Exclusion of clinical trial protocol(s)? c) Changes that may potentially generate impact to the quality or safety of the investigational product? a. If so, see item 9. d) Change from recommendations or warning issued by health authorities? a) ( ) Yes ( ) No b) ( ) Yes ( ) No c) ( ) Yes ( ) No d) ( ) Yes ( ) No
17 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 15 Reasons for Substantial Changes: a) Changes related to the active pharmaceutical ingredient? b) Changes related to the quality control and stability of the active pharmaceutical ingredient and investigational product? c) Changes related to the excipient quality control? d) Description and composition changes of the investigational product? e) Changes related to the manufacturing site of the investigational product? f) Changes related to the manufacturing process of the investigational product? g) Changes related to the manufacturing equipment of the investigational product? h) Changes related to the batch size of the investigational product? i) Changes related to the packaging of the investigational product? j) Inclusion of new dosage form? k) Changes related to the shelf life or the conservation care of the investigational product? l) Inclusion of new concentration? m) Inclusion of new dosage form? n) Changes related to the dosage? o) Use magnification? p) Addition of a new route of administration? q) Addition of a new therapeutic indication; r) Exclusion of the manufacturing place of the drug or change of primary or secondary packaging place of the product? s) Other changes? a. If so, specify: a) ( ) Yes ( ) No b) ( ) Yes ( ) No c) ( ) Yes ( ) No d) ( ) Yes ( ) No e) ( ) Yes ( ) No f) ( ) Yes ( ) No g) ( ) Yes ( ) No h) ( ) Yes ( ) No i) ( ) Yes ( ) No j) ( ) Yes ( ) No k) ( ) Yes ( ) No l) ( ) Yes ( ) No m) ( ) Yes ( ) No n) ( ) Yes ( ) No o) ( ) Yes ( ) No p) ( ) Yes ( ) No q) ( ) Yes ( ) No r) ( ) Yes ( ) No s) ( ) Yes ( ) No
18 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations 16 ANNEX II PETITION FORM FOR SUBSTANTIAL CHANGE OF THE DRUG CLINICAL DEVELOPMENT PROTOCOL Brazilian Health Surveillance Agency Clinical Research Form for Substantial Change of the Drug Clinical Development Dossier (DDMC) Document Identification (For use of the receiver body) 1. Process Number 2. Expedient (Day/ Month/ Year) Company Data 3. Applicant 4. Number of Authorization/Registration 5. Manufacturer 5. Number of Authorization/Registration Clinical Protocol Data 7. Number of the protocol process of the clinical trial and of its linked DDCM: 8. Petition Subject (codes and description) 9. Generator Factor (datavisa) 10. Title and Code of the Clinical Trial Protocol 13 Type of Substantial Amendment a) Changes in the clinical trial protocol affecting the safety or physical or mental integrity of individuals? b) Change in the scientific value of the clinical trial protocol? 11. Protocol number (version and date) 12. Trial Phase I ( ) II ( ) III ( ) IV ( ) a) ( ) Yes ( ) No b) ( ) Yes ( ) No
19 Manual for Submission of Changes, Amendments, Suspensions, and Cancellations Reasons for Substantial Amendment: a) Change of the primary objective of the clinical protocol? b) Change of the primary or secondary endpoints? c) Using new parameter to measure the primary endpoint? d) New information or interpretation of pharmacological or toxicological data, which may have impact on the risk analysis? e) Change in the criteria established for protocol completion, even though it has already done? f) Addition of experimental or placebo arms? g) Change in the number of participants expected for the study? h) Change in the inclusion and exclusion criteria? i) Reduction in the number of scheduled visits? j) Change in medical monitoring or diagnostic procedures? k) Removing the Data Monitoring Independent Committee originally planned for the study? l) Change in the investigational product? m) Change of dosage of the investigational product? n) Change in the route of administration of the investigational product? o) Change in the clinical protocol design? p) Changes in the initial statistical analysis? q) Other changes? a. If so, specify: a) ( ) Yes ( ) No b) ( ) Yes ( ) No c) ( ) Yes ( ) No d) ( ) Yes ( ) No e) ( ) Yes ( ) No f) ( ) Yes ( ) No g) ( ) Yes ( ) No h) ( ) Yes ( ) No i) ( ) Yes ( ) No j) ( ) Yes ( ) No k) ( ) Yes ( ) No l) ( ) Yes ( ) No m) ( ) Yes ( ) No n) ( ) Yes ( ) No o) ( ) Yes ( ) No p) ( ) Yes ( ) No q) ( ) Yes ( ) No
RESOLUTION-RDC Nr- 48, OF OCTOBER 6, 2009
RESOLUTION-RDC Nr- 48, OF OCTOBER 6, 2009 This resolution provides for the alteration, inclusion, suspension, reactivation and cancellation after registration of medications and sets forth other provisions.
More informationEUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/F2/BL D(2003) CT 1 Revision 2
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, ENTR/F2/BL D(2003)
More informationHaving regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;
DIRECTIVE 65/65/EEC Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 of
More informationOperational aspects of a clinical trial
Operational aspects of a clinical trial Carlo Tomino Pharm.D. Coordinator Pre-authorization Department Head of Research and Clinical Trial Italian Medicines Agency Mwanza (Tanzania), June 11, 2012 1 Declaration
More informationNATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997
NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997 Plenary of the National Health Council in its 15 th Special Meeting, held on 5 August 1997, in the exercise of its competencies, as set forth
More informationEU Clinical Trials Regulation Regulation EU 536/2014
EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes
More informationHealth Products and Food Branch. www.hc-sc.gc.ca
Health Products and Food Branch 1 HEALTH CANADA PART C DIVISION 5 - DRUGS FOR CLINICAL TRIALS INVOLVING HUMAN SUBJECTS Part C - Division 5 2 Part A: Part B: Part C: Part D: Part E: Part G: Part J: Administration
More information1.2 - Overview of Regulation of Clinical Trials in Canada
1.2 - Overview of Regulation of Clinical Trials in Canada Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationResponse of the German Medical Association
Response of the German Medical Association to the European Commission proposal for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and
More informationLEBANESE MINISTRY OF HEALTH DIRECTIVE
LEBANESE MINISTRY OF HEALTH DIRECTIVE LAYING DOWN DETAILED GUIDELINES FOR SPONSORS OF CLINICAL TRIALS March 2012 Field of Application General Considerations Trial s submission Validity of the F-MRI opinion
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More informationHaving regard to the Treaty establishing the European Community, and in particular Article 95 thereof,
L 121/34 DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2001L0020 EN 07.08.2009 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT
More informationMedical Device Directive 2007/47/EC What is New? Are we moving towards Drug Rules?
Medical Device Directive 2007/47/EC What is New? Are we moving towards Drug Rules? CEMO Congress, Paris, February 3rd, 2011 Dr. Martine Dehlinger-Kremer Vice President Global Regulatory Affairs Agenda
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, 27.03.2014 ENTR/6283/00 Rev 4 orphan\guidelines\format content
More informationSubject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
More informationClinical research: where are we with the new (Paediatric) RC trial Regulation
where are we with the new (Paediatric) RC trial Regulation, MD, PhD Ethical Committee DEEP Former member of the PDCO EMA With the aid of Fabio D'Atri European commission and Anabela Marcal of EMA The new
More informationICRIN Seminar on EU Regulation of Clinical Trials
ICRIN Seminar on EU Regulation of Clinical Trials 12 th March 2013, Dublin J. Michael Morris Director Scientific Affairs IRISH MEDICINES BOARD 28/03/2013 Slide 1 Overview Clinical Trial (CT) legislation
More informationUniversity of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
More informationREGULATION (EEC) No 2309/93
REGULATION (EEC) No 2309/93 Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use
More informationSPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT
SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption
More informationThe New EU Clinical Trial Regulation Potential Impacts on Sites
The New EU Clinical Trial Regulation Potential Impacts on Sites Angela Papa Associate Director, Clinical Management PPD Pierre-Frédéric Omnes Director, Site Start-Up and Regulatory INC Research Faculty
More informationEUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/CT 1. Revision 1
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, ENTR/CT 1 Revision
More informationOfficial Journal of the European Union. (Acts whose publication is obligatory)
27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending
More informationGuidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device List of Contents Page 1. Introduction 1.1 The Medical Device Administrative Control System and the 3 proposed legislation
More informationVOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. November 2005
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/BL D(2002) NOTICE TO APPLICANTS Revision 3 VOLUME 2A Procedures for marketing authorisation CHAPTER 1
More informationDESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004
DESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Page 1 of 17 TABLE OF CONTENTS INTRODUCTION 4 EXECUTIVE SUMMARY 4 PUBLIC HEALTH BENEFITS 5 Good clinical practice 5 Good manufacturing
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 19 July 2007 Doc. Ref: EMEA/27170/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON COMPASSIONATE USE OF MEDICINAL
More informationTemporary Authorisations for Use (ATU)
AGENCE FRANCAISE DE SECURITE SANITAIRE DES PRODUITS DE SANTE DIVISION FOR THE EVALUATION OF MEDICINAL AND BIOLOGICAL PRODUCTS Department of Products with a specific Status, Information, Therapeutic Recommendations
More informationFebruary 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
More informationNew Investigator Collaborations and Interactions: Regulatory
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité New Investigator Collaborations and Interactions: Regulatory NCIC Clinical Trials Group New Investigator Clinical Trials
More informationClinical trials regulation
Clinical trials regulation The Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use and Repealing Directive 2001/20/EC an update
More informationClinical Trials and Safety Surveillance of Drugs in Development
Clinical Trials and Safety Surveillance of Drugs in Development Hoda Eid, M.Sc., Ph.D. Manager, ADR Unit Office of Clinical Trials Therapeutic Products Directorate hoda_eid@hc-sc.gc.ca Overview Clinical
More informationRAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE
3BC6a RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE Guideline Title Rapid Alert System (RAS) in Pharmacovigilance Legislative basis Directive 65/65/EEC as amended, Council Regulation 2309/93 Date of first
More information4.1 Objectives of Clinical Trial Assessment
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
More informationGuideline on stability testing for applications for variations to a marketing authorisation
21 March 2014 EMA/CHMP/CVMP/QWP/441071/2011- Rev.2 Committee for Medicinal Products for Human Use (CHMP)/ Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on stability testing for applications
More informationEnd of consultation (deadline for comments) 14 October 2009. Adoption by Committee for advanced therapies 15 October 2010
15 October 2010 EMA/CAT/418458/2008/corr. Committee for advanced therapies (CAT) Procedural advice on the certification of quality and nonclinical data for small and medium sized enterprises developing
More informationEMA Update Clinical Trials
EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY
More informationPROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA. GCP Inspectors Working Group
European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197228/2005 Procedure no.: INS/GCP/2 PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA GCP Inspectors Working Group
More informationNRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1
NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1 2 The National Agency of Drug and Food Control (NA-DFC) is a non departmental
More informationand Regulatory Aspects
Good Clinical Practice and Regulatory Aspects Nora Espiritu MD, MPh, PhD (c) Former Executive Director of Research and Technology Transfer. Peruvian National Institute t of Health. Member of the Ethics
More informationThis is meant to be a narrative rather than a critical summary I have a lot of questions about the proposal but I will look into these separately.
REVISION OF THE CLINICAL TRIALS DIRECTIVE Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use, and Repealing Directive 2001/20/EC.
More informationExtemporaneously Prepared Early Phase Clinical Trial Materials
Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development
More informationTemplate for essential information to be provided for proposals including clinical trials / studies / investigations
Template for essential information to be provided for proposals including clinical trials / studies / investigations Document history Version 2016callsV1 September 2015 Modifications (compared to previous
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
More informationTRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
More informationTHE CLINICAL TRIALS BILL (No. XIX of 2010) Explanatory Memorandum
THE CLINICAL TRIALS BILL (No. XIX of 2010) Explanatory Memorandum 1. The object of this Bill is to provide the legal framework for the conduct of clinical trials for the purpose of discovering or verifying
More informationInvestigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
More informationEXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND
EXHIBIT COORDINATING PROVISIONS-STATE/FEDERAL LAW, ACCREDITATION STANDARDS AND GEOGRAPHIC EXCEPTIONS MARYLAND I. INTRODUCTION: Scope. To the extent of any conflict between the Agreement and this State
More informationEthics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
More informationGlossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
More informationIND Process and Review Procedures (Including Clinical Holds) CONTENTS
MANUAL OF POLICIES AND PROCEDURES CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 6030.1 REVIEW MANAGEMENT IND Process and Review Procedures (Including Clinical Holds) CONTENTS PURPOSE REFERENCES DEFINITIONS
More informationWhite Paper The EU Clinical Trials Regulation Main Changes and Challenges
White Paper The EU Clinical Trials Regulation Main Changes and Challenges Table of Contents 1. Introduction... 3 2. Main Changes and Associated Challenges... 4 2.1 Procedure for Initial Authorisation...
More informationRisk management plans an overview
Risk management plans an overview Elspeth Kay Director, Risk Management Plan Evaluation Section, Post-marketing Surveillance Branch, Monitoring and Compliance Division, TGA ARCS-TGA workshop 12 March 2015
More informationFARMAINDUSTRIA S STANDARD CODE ON PERSONAL DATA PROTECTION IN CLINICAL RESEARCH AND PHARMACOVIGILANCE
FARMAINDUSTRIA S STANDARD CODE ON PERSONAL DATA PROTECTION IN CLINICAL RESEARCH AND PHARMACOVIGILANCE - 2 - Registered at the Spanish Data Protection Agency Registry by means of the decision dated 17 June
More informationGuidance on IRB Continuing Review of Research
NOTE: THIS GUIDANCE SUPERSEDES OHRP S JANUARY 15, 2007 GUIDANCE ENTITILED GUIDANCE ON CONTINUING REVIEW. CLICK HERE FOR THE JANUARY 15, 2007 GUIDANCE. Office for Human Research Protections Department of
More informationST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
More informationRADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC
More informationComparison of Clinical Trials Registry Legislation in the Senate and House Prepared by Tannaz Rasouli, AAMC Office of Governmental Relations
Comparison of Clinical Trials Registry Legislation in the Senate and House Prepared by Tannaz Rasouli, AAMC Office of Governmental Relations Clinical Trials Registry S. 1082 (Title II, Subtitle C) H.R.
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationFederal agency for medicines and health products
Federal agency for medicines and health products A critical review of the proposed EU Clinical Trial regulation Walter Janssens Kristof Bonnarens April 2013 CT regulation - general Commission adopted the
More informationGuide to Clinical Trial Applications
Guide to Clinical Trial Applications AUT-G0001-9 DATE 29 JUNE 2015 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS
More informationPOLICY AND PROCEDURES OFFICE OF THE CENTER DIRECTOR. Table of Contents
POLICY AND PROCEDURES OFFICE OF THE CENTER DIRECTOR Tracking of Significant Safety issues in Marketed Drugs -- Use of the DARRTS Tracked Safety Issues Table of Contents PURPOSE...1 BACKGROUND...1 POLICY...2
More informationUNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM. DoD/DON-funded Research
UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM DoD/DON-funded Research Policy In 2006, the Department of the Navy (DON) enhanced its human subject protection requirements, including
More informationThe Clinical Trials Regulation EU No 536/2014: and Phase I trials
The Clinical Trials Regulation EU No 536/2014: and Phase I trials EUFEMED, Brussels, 20 May 2015 Presented by Fergus Sweeney Head, Inspections and Human Medicines Pharmacovigilance An agency of the European
More informationQualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
More informationGENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 17 July 2006 Doc. Ref. EMEA/419127/05 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PROCEDURE
More informationPlease use this template when responding to the consultation and e-mail it to:
Annex 5 Please use this template when responding to the consultation and e-mail it to: parnutsconsultation@dh.gsi.gov.uk Question 1. The Commission proposal restricts the scope of PARNUTS foods to three
More informationREQUIREMENTS FOR NATIONAL AND MUTUAL RECOGNITIONS VMP APPLICATIONS
1/13 REQUIREMENTS FOR NATIONAL AND MUTUAL RECOGNITIONS VMP APPLICATIONS 2/13 INDEX PAGE Applicable National Legislation and Community texts 3 Content of the application 3 Marketing authorisations 4 Language
More informationWHITEPAPER: SOFTWARE APPS AS MEDICAL DEVICES THE REGULATORY LANDSCAPE
WHITEPAPER: SOFTWARE APPS AS MEDICAL DEVICES THE REGULATORY LANDSCAPE White paper produced by Maetrics For more information, please contact global sales +1 610 458 9312 +1 877 623 8742 globalsales@maetrics.com
More informationPHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PART A: TRIAL INFORMATION A1. Title of Clinical Trial (as stated in proposed Protocol) Protocol No.
More informationGuidance on the In Vitro Diagnostic Medical Devices Directive 98/79/EC
Guidance on the In Vitro Diagnostic Medical Devices Directive 98/79/EC August 2013 Contents 1 Introduction...3 2 Scope of the directive...3 2.1 What is an in vitro diagnostic medical device?... 3 2.2 Specimen
More informationHealth Canada s GCP Compliance Program Part 2. GCP Information Sessions November 2010
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program Part 2 GCP Information Sessions November 2010 Inspection Program Main objectives
More informationThe European Clinical Trials Framework Update on the Draft Clinical Trials Regulation
The European Clinical Trials Framework Update on the Draft Clinical Trials Regulation Dr. Ilona Reischl BASG/AGES Austrian Agency for Health and Food Safety GmbH Content - References "Proposal for a Regulation
More informationRisk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
More informationOVERVIEW OF THE PREQUALIFICATION OF DIAGNOSTICS ASSESSMENT PROCESS. Prequalification of Diagnostics
D i a g n o s t i c s a n d L a b o r a t o r y T e c h n o l o g y OVERVIEW OF THE PREQUALIFICATION OF DIAGNOSTICS ASSESSMENT PROCESS Prequalification of Diagnostics PQDx_007 v3 20 April 2010 Table of
More informationHollie Goddard Sr. IRB Coordinator McKesson Specialty Health
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health We are responsible for acquiring, analyzing, and protecting medical information vital to providing quality patient care HIM professionals ensure
More informationGUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA : A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single Market : regulatory environment, standardisation and New Approach Pressure equipment, medical devices, metrology MEDDEV. 2.7.1 April 2003 GUIDELINES
More informationRole of the Investigational Drug Services (IDS) in the Management of Investigational Drugs
Role of the Investigational Drug Services (IDS) in the Management of Investigational Drugs Charlesworth Rae, BS, PharmD, JD Investigational Drug Pharmacist July 2012 1 Outline of Presentation I. Introduction
More informationStrategies to Prepare for Meetings with the FDA. Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA
Strategies to Prepare for Meetings with the FDA Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA Topics for Discussion Who Are We? How Do We Interact Internally? Why
More informationPDUFA REAUTHORIZATION PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017
PDUFA REAUTHORIZATION PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017 I. REVIEW PERFORMANCE GOALS A. NDA/BLA Submissions and Resubmissions B. Original Efficacy Supplements C. Resubmitted
More informationThe Australian Clinical Trial Handbook
The Australian Clinical Trial Handbook A simple, practical guide to the conduct of clinical trials to International standards of Good Clinical Practice (GCP) in the Australian context About the Therapeutic
More informationINVESTIGATOR HANDBOOK
INVESTIGATOR HANDBOOK Liberty IRB, Inc. 1450 S. Woodland Blvd., Suite 300A Deland, Florida 32720 Phone (386) 279-4318 Fax: (386)868-4563 Website: www.libertyirb.com Business hours: Monday Friday, 8:00am
More informationHealth Canada: Clinical Trial Inspection Planning. GCP Information Sessions November 2010
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada: Clinical Trial Inspection Planning GCP Information Sessions November 2010 Overview GCP Inspection Target
More informationGuidance for Industry Time and Extent Applications for Nonprescription Drug Products
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
More informationRECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING
RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING July 2006 TABLE OF CONTENTS Page 1. Introduction 2 2. Scope 2 3. Documents to be archived 2 4. Quality of essential documents 10 5.
More informationICH Topic E 8 General Considerations for Clinical Trials. Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95)
European Medicines Agency March 1998 CPMP/ICH/291/95 ICH Topic E 8 General Considerations for Clinical Trials Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95) TRANSMISSION
More informationThe New EU Clinical Trials Regulation: The Good, the Bad, the Ugly
A Full-Service International CRO The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly Dr. Martine Dehlinger-Kremer Vice President, Global Medical and Regulatory Affairs The original intent
More informationGuideline on Process Validation
1 2 3 4 29 March 2012 EMA/CHMP/CVMP/QWP/70278/2012-Rev1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 Draft Draft Agreed by CHMP /
More informationDate : Date of start of procedure: Authorisation/ positive opinion :
Substantial Amendment Notification Form (Cf. Section 3.7.b of the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use,
More informationGOVERNMENT OF THE RUSSIAN FEDERATION RESOLUTION from December 27, 2012 N 1416 APPROVAL OF THE RULES STATE REGISTRATION OF MEDICAL PRODUCTS
GOVERNMENT OF THE RUSSIAN FEDERATION RESOLUTION from December 27, 2012 N 1416 APPROVAL OF THE RULES STATE REGISTRATION OF MEDICAL PRODUCTS In accordance with Article 38 of the Federal Law "On the basis
More informationThe Regulatory Framework Gene Technology Act 2000 (Cth) and the Gene Technology Bill 2001 (WA)
For Who s Benefit? - Evaluating Genetically Modified Organisms in Western Australia from a Different Perspective Conference held by Conservation Council WA 10 October 2002 The Regulatory Framework Gene
More informationPre-market Information - Class III and IV
Pre-market Information - Class III and IV Life Sciences Council British Columbia NRC Industry Research Assistance Program Vancouver, October 29, 2007 Mary-Jane Bell, Ph.D. Medical Devices Bureau (MDB)
More informationAdoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011
1 2 3 November 2010 EMA/759784/2010 Committee for Medicinal Products for Human Use 4 5 6 7 Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and
More informationGuidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
More informationAdjuvants and Excipients
Adjuvants and Excipients The Food Safety and Inspection Service (FSIS) transferred the official responsibility to evaluate adjuvants and excipients used in Veterinary Biologics back to the Animal and Plant
More informationCompetentes en Medicamentos
VIII Encuentro de Autoridades Competentes en Medicamentos de los Países Iberoamericanos (EAMI) 12-14 de Mayo 2010 Madrid MARTIN TERBERGER Jefe de la Unidad de Productos Farmacéuticos Nuevas iniciativas
More informationGuideline on good pharmacovigilance practices (GVP)
19 April 2013 EMA/813938/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 1) Draft of first version finalised by the Agency in collaboration
More information